Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach or gastroesophageal junction adenocarcinoma.
- Your cancer stage is IIIA, IIIB, or IIIC after surgery and it has a mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) feature.
- You had a D2 or more extensive surgery and all visible cancer was removed (R0 resection).
- You are at least 18 years old and able to swallow tablets.
- Your overall health is good (ECOG 0-1) and your organ function meets specific lab criteria.
- You have not had previous immunotherapy (anti-PD-1/PD-L1) or certain other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
This trial tests whether adding the immunotherapy drug sintilimab to two different chemotherapy combinations before surgery can help people with locally advanced gastric cancer that has a specific genetic feature (dMMR). You would receive treatment before surgery to shrink the tumor, then have surgery to remove it.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.